Forado-Benatar Ilana, Caravaca-Pérez Pedro, Rodriguez-Espinosa Diana, Guzman-Bofarull Joan, Cuadrado-Payán Elena, Moayedi Yasbanoo, Broseta José Jesús, Farrero Marta
Department of Cardiology, Hospital Clínic of Barcelona, Barcelona, Spain.
Department of Nephrology and Renal Transplantation, Hospital Clínic of Barcelona, Barcelona, Spain.
Front Cardiovasc Med. 2023 Oct 4;10:1255503. doi: 10.3389/fcvm.2023.1255503. eCollection 2023.
There is a growing interest in the evaluation of tricuspid regurgitation due to its increasing prevalence and detrimental impact on clinical outcomes. Historically, it has been coined the "forgotten" defect in the field of valvular heart disease due to the lack of effective treatments to improve prognosis. However, the development of percutaneous treatment techniques has led to a new era in its management, with promising results and diminished complication risk. In spite of these advances, a comprehensive exploration of the pathophysiological mechanisms is essential to establish clear indications and optimal timing for medical and percutaneous intervention. This review will address the most important aspects related to the diagnosis, pathophysiology and treatment of tricuspid regurgitation from a cardiorenal perspective, with a special emphasis on the interaction between right ventricular dysfunction and the development of hepatorenal congestion.
由于三尖瓣反流的患病率不断上升及其对临床结局的不利影响，人们对其评估的兴趣日益浓厚。从历史上看，由于缺乏改善预后的有效治疗方法，它在心脏瓣膜病领域一直被称为“被遗忘的”缺陷。然而，经皮治疗技术的发展为其管理带来了新的时代，取得了令人鼓舞的结果，并发症风险也有所降低。尽管取得了这些进展，但全面探索病理生理机制对于明确药物和经皮干预的适应证及最佳时机至关重要。本综述将从心肾角度探讨与三尖瓣反流的诊断、病理生理及治疗相关的最重要方面，特别强调右心室功能障碍与肝肾淤血发展之间的相互作用。
